drugset
drugset / Trial / NCT04147910

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

NCT04147910 ↗

Phase 1 Completed 8 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelOther

Summary

This is an open-label, single-dose study in healthy male subjects to investigate the absorption, metabolism, and excretion (AME) of KW-6356.

Timeline

Start
2019-08-21
Primary completion
2019-10-02
Completion
2019-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject SIPAGLADENANT Small molecule — Oral

Indications

No indication recorded.